Cuprous oxide nanoparticles incorporated into a polymeric matrix embedded in fabrics to prevent spread of SARS-CoV-2

[Display omitted] •Cotton and PP fabrics coated with a chitosan matrix containing Cu2O@SDS NPs were developed.•The coating of the fabrics was carried out by using a dip-assisted layer-by-layer technology.•Low curing temperature and without expensive equipment or toxic chemicals were requirement.•The...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics Vol. 636; p. 122790
Main Authors: Usseglio, Nadina, Onnainty, Renée, Konigheim, Brenda, Aguilar, Javier, Petiti, Juan Pablo, Lingua, Giuliana, Leimgruber, Carolina, Bonafé Allende, Juan Cruz, Torres, Alicia, Granero, Gladys
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 05-04-2023
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Cotton and PP fabrics coated with a chitosan matrix containing Cu2O@SDS NPs were developed.•The coating of the fabrics was carried out by using a dip-assisted layer-by-layer technology.•Low curing temperature and without expensive equipment or toxic chemicals were requirement.•The coating of fabrics developed provides a reduction in the infectivity of the SARS-CoV-2 virus. This paper describes the development of a coating for cotton and polypropylene (PP) fabrics based on a polymeric matrix embedded with cuprous oxide nanoparticles (Cu2O@SDS NPs) in order to inactivate SARS-CoV-2 and manufactured by a simple process using a dip-assisted layer-by-layer technology, at low curing temperature and without the need for expensive equipment, capable of achieving disinfection rates of up to 99%. The polymeric bilayer coating makes the surface of the fabrics hydrophilic, enabling the transportation of the virus-infected droplets to achieve the rapid inactivation of SARS-CoV-2 by contact with the Cu2O@SDS NPs incorporated in the coated fabrics.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2023.122790